2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Dermatologic
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
142
Gastrointestinal Stromal Tumors
71
Leukemia
69
Leukemia, Myeloid, Chronic-Phase
50
Precursor Cell Lymphoblastic Leukemia-Lymphoma
43
Blast Crisis
22
Neoplasms
15
Brain Neoplasms
15
Philadelphia Chromosome
14
Melanoma
13
Sarcoma
12
Neoplasm Metastasis
12
Leukemia, Myeloid, Acute
12
Leukemia, Myeloid, Accelerated Phase
12
Glioblastoma
12
Lung Neoplasms
11
Prostatic Neoplasms
10
Leukemia, Myeloid
9
Gliosarcoma
9
Glioma
8
Breast Neoplasms
8
Primary Myelofibrosis
7
Leukemia, Myelomonocytic, Chronic
7
Central Nervous System Neoplasms
7
Astrocytoma
7
Recurrence
6
Polycythemia Vera
6
Ovarian Neoplasms
6
Oligodendroglioma
6
Myeloproliferative Disorders
6
Interventions
Ipilimumab
29
Nivolumab
23
pembrolizumab
14
incomplete Freund's adjuvant
10
Cyclophosphamide
10
Melphalan
9
Interleukin-2
9
CTLA-4 Antigen
8
tebentafusp
7
sargramostim
7
Temozolomide
7
MART-1 Antigen
7
Dacarbazine
7
Ranibizumab
6
montanide ISA 51
5
fludarabine phosphate
5
fludarabine
5
Sunitinib
5
Radiosurgery
5
Carboplatin
5
Blood Specimen Collection
5
Bevacizumab
5
aldesleukin
4
aflibercept
4
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
Granulocyte-Macrophage Colony-Stimulating Factor
4
Biopsy
4
trametinib
3
sotrastaurin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uveal Melanoma
×
Imatinib Mesylate
×
Clear all
NCT01046487
2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1
Completed
26 enrolled